Aspen Neuroscience earns funding for stem cell therapy from a group of venture capital firms.
An autologous stem cell therapy for Parkinson’s disease (PD), with a potential to alter disease progression, received a boost when the programme received a seed funding totalling $6.5m from a group of venture capitalist firms. The funding is likely to help the company in advancing the programme to different stages of clinical development.
Aspen - Neuroscience - Disease - Patient - Cells
Aspen Neuroscience aims to tackle the disease by using the patient’s own cells obtained via a skin biopsy and turning that into pluripotent stem cells that are then differentiated into dopamine-releasing neurons, which can be introduced back into the patient with the objective of replacing neurons that are damaged by onset of PD. The autologous approach is proposed to help in circumventing the issue of immunogenicity that is otherwise associated with an allogeneic approach.
According to key opinion leaders (KOLs) that were interviewed for GlobalData’s report on Stem Cells in Neurology, the main consensus among these KOLs was in favour of an allogeneic approach of...
Wake Up To Breaking News!
Millions in tribute, but not a penny left for charity.